0001246360-13-004613.txt : 20131003
0001246360-13-004613.hdr.sgml : 20131003
20131003160708
ACCESSION NUMBER: 0001246360-13-004613
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131001
FILED AS OF DATE: 20131003
DATE AS OF CHANGE: 20131003
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SYNAGEVA BIOPHARMA CORP
CENTRAL INDEX KEY: 0000911326
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 561808663
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 HAYDEN AVE.
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: (781) 357-9900
MAIL ADDRESS:
STREET 1: 33 HAYDEN AVE.
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: TRIMERIS INC
DATE OF NAME CHANGE: 19970516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Goldberg Mark Alan
CENTRAL INDEX KEY: 0001532475
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23155
FILM NUMBER: 131133812
MAIL ADDRESS:
STREET 1: 128 SPRING STREET, SUITE 520
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
form.xml
PRIMARY DOCUMENT
X0306
4
2013-10-01
false
0000911326
SYNAGEVA BIOPHARMA CORP
GEVA
0001532475
Goldberg Mark Alan
33 HAYDEN AVE
LEXINGTON
MA
02421
false
true
false
false
SVP,Medical&Regulatory Affairs
Common Stock
2013-10-01
4
M
false
7000
8.73
A
7267
D
Common Stock
2013-10-01
4
S
false
3230
63.97
D
4037
D
Common Stock
2013-10-01
4
S
false
3770
64.61
D
267
D
Stock Option (Right to Buy)
8.73
2013-10-01
4
M
false
7000
0
D
2021-09-22
Common Stock
7000
81703
D
The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2012.
The Stock Option granted the reporting person an option to purchase 88,703 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 09/22/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $63.35 to $64.34 The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $64.35 to $65.00 The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
/s/ Stephen F. Mahoney, Attorney-in-Fact
2013-10-03